Choledocholithiasis — the presence of gallstones in the common bile duct (CBD) — occurs in 10–20% of patients with symptomatic cholelithiasis and is the leading cause of acute pancreatitis. [1-2] Management is driven by risk stratification using the ASGE algorithm (clinical, laboratory, and imaging parameters) to determine the need for ERCP, MRCP/EUS, or cholecystectomy alone. [1][3]
The following risk-stratification flowchart illustrates the management approach based on predicted likelihood of CBD stones:
1. History
- Pain characterization: Sudden-onset, steady, intense RUQ or epigastric pain; may radiate to the right scapula or back. Unlike biliary colic (resolves <5 hours), pain from choledocholithiasis tends to persist >6 hours. [2]
- Timing/triggers: Postprandial (especially fatty meals); may be recurrent or progressive.
- Associated symptoms: Nausea, vomiting, dark urine, pale/acholic stools, pruritus, jaundice.
- Important negatives: Absence of fever (argues against cholangitis); absence of epigastric pain radiating to the back (argues against pancreatitis).
2. Alarm Features
- Charcot triad (fever, jaundice, RUQ pain) → ascending cholangitis [2][5]
- Reynolds pentad (Charcot triad + hypotension + altered mental status) → suppurative cholangitis/biliary sepsis — requires emergent biliary drainage [6]
- Acute epigastric pain with elevated lipase → gallstone pancreatitis
- Total bilirubin >4 mg/dL with CBD dilation → high-risk for persistent stone, proceed directly to ERCP [1]
- Sepsis (tachycardia, hypotension, fever, leukocytosis) — mortality in severe cholangitis can reach 10% at 7 days [6]
3. Medications
- Pain management:
- NSAIDs are first-line (e.g., ketorolac 15–30 mg IV) — superior to antispasmodics (NNT = 3 vs placebo), non-inferior to opioids with fewer adverse effects [2][7]
- Opioids may cause sphincter of Oddi spasm; use sparingly [2]
- IV acetaminophen 1 g can be combined with low-dose morphine for equivalent analgesia [8]
- Antibiotics (if cholangitis suspected):
- Community-acquired, mild-moderate: piperacillin/tazobactam provides excellent coverage [9-10]
- Severe/healthcare-associated: consider carbapenems (imipenem/meropenem) [9][11]
- Target organisms: Enterobacteriaceae (E. coli, Klebsiella), Enterococcus spp. [9][12]
- Duration: 3–5 days with adequate source control [13]
- Avoid: Ursodeoxycholic acid is not indicated for acute management of CBD stones [2]
4. Diet
- NPO in the acute setting, especially if ERCP or surgery is anticipated
- Low-fat diet upon resumption of oral intake
- Long-term: avoidance of high-fat meals reduces recurrent biliary symptoms
- Rapid weight loss is a risk factor for gallstone formation — counsel on gradual weight loss strategies [2]
5. Review of Systems
- GI: Nausea, vomiting, anorexia, steatorrhea, acholic stools, abdominal distension
- Constitutional: Fever, chills, rigors (cholangitis)
- Dermatologic: Jaundice, scleral icterus, pruritus
- Urologic: Dark (tea-colored) urine
- Cardiovascular: Chest pain (biliary-cardiac reflex/"cholecardia syndrome" can mimic ACS with ST-T wave changes) [14-15]
6. Collateral History and Family History
- Prior episodes of biliary colic, cholecystitis, or known gallstones
- Prior ERCP, sphincterotomy, or cholecystectomy (alters CBD dilation thresholds: >8 mm post-cholecystectomy vs >6 mm with gallbladder in situ) [1]
- Family history of gallstone disease (genetic predisposition to cholesterol supersaturation) [1]
- Medication history: estrogen/OCP use, octreotide, fibrates, ceftriaxone — all increase gallstone risk
7. Risk Factors
- Female sex, age >55 years, obesity, multiparity [1-2]
- Type 2 diabetes mellitus, nonalcoholic fatty liver disease [2]
- Rapid weight loss (diet or bariatric surgery) [2][16]
- Hemolytic anemia (pigment stones) [2]
- Prior biliary instrumentation/sphincterotomy (increases risk of recurrent CBD stones and resistant organisms) [12]
- Ethnicity: Native American, Hispanic populations at higher risk
8. Differential Diagnosis
- Acute cholecystitis — persistent RUQ pain >6 hours, positive Murphy sign (LR+ 11.5–21.3), sonographic gallbladder wall thickening/pericholecystic fluid [2]
- Gallstone pancreatitis — epigastric pain radiating to back, elevated lipase >3× ULN [2]
- Cholangiocarcinoma / pancreatic head carcinoma — painless jaundice, weight loss, Courvoisier sign [17-18]
- Primary sclerosing cholangitis — beaded appearance of bile ducts on MRCP, associated with IBD [17]
- Mirizzi syndrome — extrinsic CBD compression by impacted cystic duct stone [1]
- Sphincter of Oddi dysfunction — recurrent biliary-type pain post-cholecystectomy without stones
- Hepatitis — transaminase-predominant elevation, viral serologies
- Periampullary tumors (ampullary carcinoma, duodenal carcinoma) [17]
9. Past Medical History
- Prior gallstone disease, cholecystectomy, biliary surgery
- History of ERCP or sphincterotomy
- Chronic liver disease, cirrhosis
- Inflammatory bowel disease (associated with PSC)
- Hemolytic disorders (sickle cell, hereditary spherocytosis)
- Bariatric surgery or recent significant weight loss
10. Physical Exam
- Vitals: Fever (cholangitis), tachycardia, hypotension (sepsis)
- Abdomen: RUQ tenderness; Murphy sign (more specific for cholecystitis); peritoneal signs suggest perforation or severe inflammation
- Skin/eyes: Jaundice, scleral icterus
- General: Altered mental status (Reynolds pentad — biliary sepsis)
- Courvoisier sign (palpable, nontender gallbladder with jaundice) → suggests malignant obstruction rather than stone disease
11. Lab Studies
- Initial panel:
- CBC with differential (leukocytosis in cholangitis)
- CMP including total and direct bilirubin, ALT, AST, ALP, GGT
- Lipase (rule out gallstone pancreatitis)
- Coagulation studies (PT/INR — may be prolonged with biliary obstruction)
- Blood cultures × 2 if cholangitis suspected
- Lactate if sepsis concern
- Expected pattern: Elevated bilirubin, ALP, and GGT (cholestatic pattern); transaminases may be markedly elevated acutely then trend down [2][19]
- Trending labs: Rising bilirubin, ALP, or transaminases at 24–48 hours has a PPV of 31% and NPV of 92% for persistent CBD stones. Total bilirubin >4 mg/dL at 48 hours has 94% specificity for persistent stones [19]
12. Imaging
- First-line: RUQ ultrasound
- Can identify CBD stones (LR+ 8.1, LR− 0.3) and CBD dilation (>6 mm with gallbladder in situ) [2]
- Limited sensitivity for distal CBD stones
- MRCP — sensitivity 84–92%, specificity 92–97%; noninvasive; identifies stones, strictures, and malignancy [2][19]
- EUS — sensitivity 92–98%, specificity 89%; can be combined with same-session ERCP [2][20]
- ERCP — both diagnostic and therapeutic; reserved for high-risk patients or confirmed stones; carries 6–15% adverse event rate [1]
- CT abdomen — low sensitivity for CBD stones but useful to exclude other pathology
- When imaging is unnecessary: Low-risk patients (no abnormal LFTs, no CBD dilation, age <55) → proceed to cholecystectomy without further biliary imaging [1]
13. Special Tests
- ASGE Risk Stratification Algorithm (2019): [1]
- High risk (→ proceed to ERCP): CBD stone on imaging, OR total bilirubin >4 mg/dL + CBD dilation, OR ascending cholangitis
- Intermediate risk (→ EUS, MRCP, or IOC): Abnormal LFTs, age >55, OR dilated CBD
- Low risk (→ cholecystectomy ± IOC): No risk factors
- Intraoperative cholangiography (IOC): Useful during cholecystectomy for intermediate-risk patients; avoids unnecessary ERCP [19]
- Point-of-care ultrasound (POCUS): Can identify gallstones and CBD dilation at bedside in the ED
14. ECG
- Cholecardia syndrome: Biliary disease can cause ECG changes via vagally mediated cardio-biliary reflex, including: [14-15][21]
- ST-segment depression or elevation
- Deep T-wave inversions
- QTc prolongation
- Sinus bradycardia or AV block (Cope sign)
- These changes resolve with treatment of the biliary pathology (e.g., post-ERCP) [15]
- Pearl: Obtain ECG in patients with biliary disease and chest pain to differentiate from ACS; troponin may be mildly elevated. Serial monitoring and clinical context are essential to avoid unnecessary cardiac catheterization [15][21]
15. Assessment
- Choledocholithiasis presents on a spectrum from incidental finding to life-threatening biliary sepsis
- Severity stratification is driven by the presence or absence of cholangitis (Tokyo Guidelines Grade I–III) and the ASGE risk algorithm [1][10]
- Stones may pass spontaneously — only 30–40% of patients with lab values predictive of CBD stones are found to have stones at ERCP [3][19]
- Complications: Ascending cholangitis (2–9% of gallstone admissions), gallstone pancreatitis (33–50% of CBD stone cases), biliary stricture, hepatic abscess [18]
16. Treatment Plan
- Initial stabilization:
- IV fluid resuscitation, NPO, pain control (ketorolac IV first-line) [2]
- Empiric antibiotics if cholangitis suspected (piperacillin/tazobactam 3.375–4.5 g IV q6–8h) [9-10]
- Blood cultures before antibiotics
- Definitive management based on risk:
- High risk / cholangitis: ERCP with sphincterotomy and stone extraction within 24 hours for moderate-severe cholangitis [22-23]
- Intermediate risk: EUS or MRCP → ERCP if stones confirmed; alternatively, IOC at time of cholecystectomy [1][19-20]
- Low risk: Laparoscopic cholecystectomy without further biliary workup [1]
- Difficult/large stones: Papillary balloon dilation after sphincterotomy, intraductal lithotripsy (laser or electrohydraulic), or temporary biliary stent placement [1]
- Cholecystectomy: Same-admission cholecystectomy is recommended after CBD clearance to prevent recurrent biliary events. ERCP alone without cholecystectomy in elderly patients is associated with 9.2% readmission for recurrent biliary disease vs 2.2% with cholecystectomy [1][24]
- Single-stage approaches (intraoperative ERCP or laparoscopic CBD exploration at time of cholecystectomy) are associated with shorter hospital stays and decreased morbidity compared with two-stage approaches [25]
17. Disposition
- Admit:
- Ascending cholangitis (any severity)
- Gallstone pancreatitis
- Persistent pain, inability to tolerate PO, hemodynamic instability
- High-risk patients awaiting ERCP
- Significant comorbidities or elderly patients requiring observation
- Observation: Intermediate-risk patients awaiting MRCP/EUS with stable vitals and controlled pain
- Discharge (rare from ED): Incidentally found mild CBD dilation with normal labs, no pain, and reliable follow-up
- Consult triggers:
- GI/ERCP: All confirmed or high-risk suspected choledocholithiasis
- Surgery: For cholecystectomy planning; emergent if perforation, peritonitis, or failed ERCP
- IR: If ERCP fails or is not feasible (e.g., altered anatomy) — percutaneous transhepatic biliary drainage
18. Follow Up / Return Precautions
- Follow-up timing: Surgical follow-up within 1–2 weeks post-discharge for cholecystectomy planning if not performed during index admission
- Return immediately for: Fever/chills, worsening abdominal pain, jaundice, dark urine/pale stools, persistent vomiting, signs of sepsis
- Post-ERCP monitoring: Watch for post-ERCP pancreatitis (most common complication, 4–10%), bleeding, perforation [2]
- Expected course: Most patients improve rapidly after stone clearance; same-admission cholecystectomy prevents recurrence [1][24]
- Patient counseling: Emphasize importance of definitive cholecystectomy — ERCP alone does not prevent future gallstone complications. Low-fat diet until surgery. Avoid rapid weight loss programs [2][16]
References
1. ASGE Guideline on the Role of Endoscopy in the Evaluation and Management of Choledocholithiasis. — Buxbaum JL, Abbas Fehmi SM, Sultan S, et al. Gastrointestinal Endoscopy. 2019.
2. Gallstone Disease: Common Questions and Answers. — Patel H, Jepsen J. American Family Physician. 2024.
3. Quality Indicators for ERCP. — Anderson MA, Cote GA, Keswani RN, et al. The American Journal of Gastroenterology. 2026.
4. Gallstones. — Piero Portincasa, David Q.‐H. Wang Yamada's Atlas of Gastroenterology. 2022.
5. Acute Cholangitis: Causes, Diagnosis, and Management. — An Z, Braseth AL, Sahar N. Gastroenterology Clinics of North America. 2021.
6. Machine-Learning-Derived Online Prediction Models of Outcomes for Patients With Cholelithiasis-Induced Acute Cholangitis: Development and Validation in Two Retrospective Cohorts. — Huang S, Zhou Y, Liang Y, et al. EClinicalMedicine. 2024.
7. Non-Steroid Anti-Inflammatory Drugs for Biliary Colic. — Fraquelli M, Casazza G, Conte D, Colli A. The Cochrane Database of Systematic Reviews. 2016.
8. Guidelines for Reasonable and Appropriate Care in the Emergency Department 2 (GRACE-2): Low-Risk, Recurrent Abdominal Pain in the Emergency Department. — Broder JS, Oliveira J E Silva L, Bellolio F, et al. Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine. 2022.
9. Use of Microbiological and Patient Data for Choice of Empirical Antibiotic Therapy in Acute Cholangitis. — Kruis T, Güse-Jaschuck S, Siegmund B, Adam T, Epple HJ. BMC Gastroenterology. 2020.
10. Tokyo Guidelines 2018: Antimicrobial Therapy for Acute Cholangitis and Cholecystitis. — Gomi H, Solomkin JS, Schlossberg D, et al. Journal of Hepato-Biliary-Pancreatic Sciences. 2018.
11. Bile Bacterial Flora and Its in Vitro Resistance Pattern in Patients With Acute Cholangitis Resulting From Choledocholithiasis. — Karpel E, Madej A, Bułdak Ł, et al. Scandinavian Journal of Gastroenterology. 2011.
12. Microbiology of Bile Aspirates Obtained at ERCP in Patients With Suspected Acute Cholangitis. — Gromski MA, Gutta A, Lehman GA, et al. Endoscopy. 2022.
13. Source Control in Emergency General Surgery: WSES, GAIS, SIS-E, SIS-A Guidelines. — Coccolini F, Sartelli M, Sawyer R, et al. World Journal of Emergency Surgery : WJES. 2023.
14. Cardiac Complications Caused by Biliary Diseases: A Review of Clinical Manifestations, Pathogenesis and Treatment Strategies of Cholecardia Syndrome. — Li Y, Li J, Leng A, Zhang G, Qu J. Pharmacological Research. 2024.
15. Sequential Electrocardiography Changes. — Yu S, Lv H, Liu M. JAMA Internal Medicine. 2025.
16. Gallstones: Prevention, Diagnosis, and Treatment. — Lammert F, Wittenburg H. Seminars in Liver Disease. 2024.
17. Endoscopic Ultrasound Versus Magnetic Resonance Cholangiopancreatography for Common Bile Duct Stones. — Giljaca V, Gurusamy KS, Takwoingi Y, et al. The Cochrane Database of Systematic Reviews. 2015.
18. Ultrasound Versus Liver Function Tests for Diagnosis of Common Bile Duct Stones. — Gurusamy KS, Giljaca V, Takwoingi Y, et al. The Cochrane Database of Systematic Reviews. 2015.
19. Management of Gallstone Pancreatitis: A Review. — McDermott J, Kao LS, Keeley JA, Nahmias J, de Virgilio C. JAMA Surgery. 2024.
20. EUS Versus MRCP to Perform ERCP in Patients With Intermediate Likelihood of Choledocholithiasis: A Randomised Controlled Trial. — Jagtap N, Kumar JK, Chavan R, et al. Gut. 2022.
21. Electrocardiographic Changes in Cardiac Patients With Acute Gallbladder Disease. — Krasna MJ, Flancbaum L. The American Surgeon. 1986.
22. Urgent and Emergency Endoscopic Retrograde Cholangiopancreatography for Gallstone-Induced Acute Cholangitis and Pancreatitis. — Mukai S, Itoi T, Tsuchiya T, et al. Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society. 2023.
23. Pancreatic and Biliary Endoscopy. — Brugge WR, Van Dam J. The New England Journal of Medicine. 1999.
24. Management of Choledocholithiasis in the Elderly: Same-Admission Cholecystectomy Remains the Standard of Care. — Berndtson AE, Costantini TW, Smith AM, et al. Surgery. 2022.
25. One- And Two-Stage Approaches to Common Duct Stones. — Smith SM, Kelley JK, Zambito GM, Banks-Venegoni AL. The American Surgeon. 2025.